Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Is OncoGenex Pharmaceuticals Inc (OGXI) A Good Stock To Buy?

Hedge funds and other investment firms run by legendary investors like Israel Englander and Ray Dalio are entrusted to manage billions of dollars of accredited investors’ money because they are without peer in the resources they use to identify the best investments for their chosen investment horizon. Moreover, they are more willing to invest a greater amount of their resources in small-cap stocks than big brokerage houses, and this is often where they generate their outperformance, which is why we pay particular attention to their best ideas in this space.

OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI) shareholders have witnessed a decrease in enthusiasm from smart money of late. The market sentiment surrounding OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI) looked the same, with its shares losing 4.29% value throughout the quarter. We will find out more about the hedge funds that maintained their stakes in OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI), at the end of September.

In order to understand the hedge fund behavior towards stocks with a similar market cap, we will also compare OGXI to other stocks, including Verastem Inc (NASDAQ:VSTM), The Bon-Ton Stores, Inc. (NASDAQ:BONT), and Gulf Resources, Inc. (NASDAQ:GURE) to get a better sense of its popularity.

Follow Achieve Life Sciences Inc. (NASDAQ:ACHV)
Trade (NASDAQ:ACHV) Now!

In the eyes of most market participants, hedge funds are viewed as slow, outdated financial vehicles of the past. While there are greater than 8000 funds in operation today, We hone in on the moguls of this club, around 700 funds. It is estimated that this group of investors orchestrates bulk of all hedge funds’ total capital, and by tailing their first-class investments, Insider Monkey has spotted a few investment strategies that have historically outperformed Mr. Market. Insider Monkey’s small-cap hedge fund strategy surpassed the S&P 500 index by 12 percentage points per annum for a decade in their back tests.

Now, we’re going to take a look at the new action regarding OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI).

What have hedge funds been doing with OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI)?

At the end of the third quarter, a total of 5 of the hedge funds tracked by Insider Monkey were long this stock, a decrease of 29% from the second quarter. With hedge funds’ capital changing hands, there exists a few key hedge fund managers who were upping their stakes substantially (or already accumulated large positions).

When looking at the institutional investors followed by Insider Monkey, Renaissance Technologies has the largest position in OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI), worth close to $1.6 million, corresponding to less than 0.1% of its total 13F portfolio. Sitting at the No. 2 spot is Charles Davidson of Wexford Capital, with a $0.7 million position; 0.1% of its 13F portfolio is allocated to the stock. Some other professional money managers that are bullish include Israel Englander’s Millennium Management, Jonathan Lourie and Stuart Fiertz’s Cheyne Capital, and Richard Driehaus’ Driehaus Capital.

Due to the fact that OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI) has experienced a bearish sentiment from the smart money, logic holds that there was a specific group of hedgies that elected to cut their full holdings last quarter. At the top of the heap, Mark Lampert’s Biotechnology Value Fund / BVF Inc dumped the biggest stake of the 700 funds watched by Insider Monkey, totaling an estimated $2.4 million in stock, and Chao Ku’s Nine Chapters Capital Management was right behind this move, as the fund said goodbye to about $0.2 million worth of shares. These moves are interesting, as total hedge fund interest dropped by 2 funds last quarter.

Let’s go over hedge fund activity in other stocks – not necessarily in the same industry as OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI) but similarly valued. These stocks are Verastem Inc (NASDAQ:VSTM), The Bon-Ton Stores, Inc. (NASDAQ:BONT), Gulf Resources, Inc. (NASDAQ:GURE), and Aviat Networks Inc (NASDAQ:AVNW). This group of stocks’ market valuations are similar to OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI)’s market valuation.

Ticker No of HFs with positions Total Value of HF Positions (x1000) Change in HF Position
VSTM 4 3969 -9
BONT 8 15793 -1
GURE 4 2603 0
AVNW 5 14921 -1

As you can see, these stocks had an average of 5 hedge funds with bullish positions and the average amount invested in these stocks was $9 million. That figure was $3 million in OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI)’s case. The Bon-Ton Stores, Inc. (NASDAQ:BONT) is the most popular stock in this table. On the other hand, Verastem Inc (NASDAQ:VSTM) is the least popular one with only 4 bullish hedge fund positions. OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI) is not the least popular stock in this group, but hedge fund interest is still below average. This is a slightly negative signal and we’d rather spend our time researching stocks that hedge funds are piling on. In this regard, The Bon-Ton Stores, Inc. (NASDAQ:BONT) might be a better candidate to consider a long position.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.